BAMCO Inc
ADAP

BAMCO Inc’s Adaptimmune Therapeutics ADAP Stock Holding History

BAMCO Inc’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-172,669
Closed -$694K – 350
2019
Q2 		$694K Buy
172,669
+10,000
+6% +$40.8K ﹤0.01% 308
2019
Q1 		$699K Hold
162,669
– – ﹤0.01% 301
2018
Q4 		$935K Sell
162,669
-445,030
-73% -$3.28M ﹤0.01% 302
2018
Q3 		$8.24M Buy
607,699
+262,330
+76% +$2.75M 0.03% 218
2018
Q2 		$4.1M Buy
+345,369
New +$4.31M 0.02% 251

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BAMCO Inc's ADAP Position: Q3 2019 in Review

BAMCO Inc sold out of Adaptimmune Therapeutics (ADAP) in Q3 2019, closing a stake of 172,669 shares — an estimated $694K sold.

BAMCO Inc first reported a position in ADAP in Q2 2018 and held it in 5 quarters. The position peaked at $8.24M in Q3 2018. 49 funds tracked by Wall St. Rank hold ADAP as of Q3 2019.

  • BAMCO Inc reported no remaining Adaptimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • BAMCO Inc sold 172,669 Adaptimmune Therapeutics shares in Q3 2019, an estimated $694K.
  • BAMCO Inc first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 5 quarters.
  • BAMCO Inc's Adaptimmune Therapeutics position peaked at $8.24M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2019.

Based on BAMCO Inc's 13F filing for Q3 2019, filed 14 Nov 2019.